Amplia Therapeutics Limited (ASX: ATX) is an Australian, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.
Amplia’s pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading cancer and drug discovery researchers at Australia’s top cancer research institutes. Amplia was established to advance these promising drugs into clinical development and commercialisation.
The first of these drugs, AMP945, is a highly selective and potent inhibitor of FAK and is currently in clinical development for pancreatic cancer and advanced preclinical development for IPF. Orphan Drug Designations for both these indications have been granted by the US FDA.
Amplia’s second pipeline drug, AMP886 inhibits FAK and also inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is currently being evaluated in preclinical models of cancer.
Amplia’s Board and Management team includes highly experienced and well-credentialled life-science executives who have extensive international experience in drug development, pharmaceuticals, and life-sciences deal-making.